BRIEF-EMA recommends conditional approval for J&J's blood cancer drug
April 01, 2016 at 11:37 AM EDT
* EU Medicines Agency recommends conditional approval of Johnson & Johnson and Genmab A/S's Daratumumab to treat multiple myeloma
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.